Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Pozycja w akcjach #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Cena akcji
$0.04959193
Ostatnia synchronizacja: 2025-03-17
Kapitalizacja rynkowa
$79.94M
Zmiana (1 dzień)
13.49%
Zmiana (1 rok)
0.00%
Kraj
SE
Handel Abliva AB (publ) (ABLI)

Kategoria

Historia ceny akcji dla Abliva AB (publ) (ABLI)
Najwyższa cena zamknięcia: $0.04 dnia 2025-03-01

Najniższa cena zamknięcia: $0.44 dnia 2008-10-01
Historia cen akcji firmy Abliva AB (publ) od 2008 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2025 83.38%
2024 -0.37%
2023 44.87%
2022 -73.02%
2021 -34.26%
2020 -30.47%
2019 -20.24%
2018 -46.40%
2017 4.60%
2016 -62.61%
2015 -86.83%
2014 208.88%
2013 -8.57%
2012 59.62%
2011 -55.60%
2010 208.76%
2009 91.09%
2008 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH